<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Management of inclusion body myositis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Management of inclusion body myositis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Management of inclusion body myositis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Thomas E Lloyd, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lisa Christopher-Stine, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ira N Targoff, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeremy M Shefner, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Philip Seo, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 29, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sporadic inclusion body myositis (IBM) is classified along with polymyositis, dermatomyositis, and autoimmune necrotizing myopathy as one of the idiopathic inflammatory myopathies. However, despite some histologic similarities, the clinicopathologic manifestations, treatment, and prognosis of IBM are clearly distinct from the other disorders  (
         <a class="graphic graphic_table graphicRef74076" href="/z/d/graphic/74076.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5160.html" rel="external">
          "Initial treatment of dermatomyositis and polymyositis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5133.html" rel="external">
          "Treatment of recurrent and resistant dermatomyositis and polymyositis in adults"
         </a>
         .)
        </p>
        <p>
         The treatment and prognosis of IBM will be reviewed here. The clinical manifestations and diagnosis are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/5163.html" rel="external">
          "Clinical manifestations and diagnosis of inclusion body myositis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H324856754">
         <span class="h1">
          GOALS OF THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary goal of therapy in inclusion body myositis (IBM) is to optimize muscle strength and function. Given the slowly progressive and variable course of the disease, it can be quite challenging to determine if treatment leads to an objective improvement in or stabilization of muscle strength [
         <a href="#rid1">
          1
         </a>
         ]. It is well known that immunosuppressive medications will lower muscle enzyme levels in IBM patients despite continued progression of weakness, and also that creatine kinase (CK) levels decrease with muscle atrophy [
         <a href="#rid2">
          2,3
         </a>
         ]. Therefore, CK levels cannot be used to monitor response to therapy in this disease. Based on the existing data, we only consider a trial of immunosuppressive medications in IBM patients with an atypical presentation or in patients with another autoimmune disease.
        </p>
        <p class="headingAnchor" id="H327954467">
         <span class="h1">
          OUR APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Almost all patients with any degree of limitation in activities of daily living will benefit from physical and occupational therapy evaluation. Patients with dysphagia should be evaluated by a speech therapist. Exercise is likely beneficial in all patients. In contrast to other inflammatory myopathies such as dermatomyositis and polymyositis, inclusion body myositis (IBM) is relatively resistant to standard immunomodulatory therapies [
         <a href="#rid4">
          4,5
         </a>
         ]. However, there is limited evidence that some subgroups of patients may benefit from such therapy, in particular those with another systemic autoimmune disease such as Sjögren's disease or systemic lupus erythematosus [
         <a href="#rid6">
          6-8
         </a>
         ]. We typically suggest a trial of immunosuppressive treatment when the diagnosis of IBM is uncertain, or in cases where there appears to be overlap with polymyositis as evidenced by early and prominent proximal weakness (ie, neck flexors, arm abductors, hip flexors). (See
         <a class="local">
          'Immunosuppressive therapy in selected patients'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H274148797">
         <span class="h2">
          Nonpharmacologic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal treatment for IBM is not known, and most interventions have demonstrated only limited benefit. Nonpharmacologic interventions such as physical therapy, occupational therapy, and/or speech therapy can be helpful in all patients to achieve the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Provide an exercise program to maintain strength as long as possible
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Address concerns about falling and the use of orthoses and assistive devices such as canes (preferably four-point canes) and walkers
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Address difficulties with the activities of daily living such as finger flexor weakness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Help learn techniques to minimize the risk of aspiration in patients with dysphagia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Provide nutritional support or dietary counseling in patients with dysphagia or obesity, respectively
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H321937820">
         <span class="h3">
          Exercise
         </span>
         <span class="headingEndMark">
          —
         </span>
         All IBM patients should be evaluated by a physical therapist with experience in neuromuscular diseases to develop an individualized exercise program. We favor the combined aerobic and functional muscle strengthening program that is described in a study of IBM patients [
         <a href="#rid9">
          9
         </a>
         ]. Increasing evidence has shown that exercise is beneficial in IBM [
         <a href="#rid9">
          9-12
         </a>
         ]. Since strenuous exercise has long been known to elevate muscle enzyme levels, there has long been a theoretical but unfounded concern that exercise could accelerate muscle damage in myositis. However, data suggest that frequent, low resistance, endurance exercises are not harmful and in fact are likely beneficial. Although strengthening exercises focus on muscles that are minimally to moderately weak, passive range-of-motion exercises for severely weak muscles are also important to prevent joint contractures. Patient education is critical to avoid tendon injuries and to manage delayed-onset muscle soreness and fatigue with exercise. At our center, we have seen improvement in muscle strength in IBM patients with a supervised exercise program, and we recommend reevaluation by a therapist every four months to assess and potentially adjust the exercise regimen. For ambulatory patients who are unwilling or unable to participate in a regimented daily home exercise program, we recommend frequent, low-impact aerobic exercise such as aquatherapy or use of stationary bike.
        </p>
        <p class="headingAnchor" id="H4229628357">
         <span class="h3">
          Ambulation and fall prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gait difficulties and falls are a major source of morbidity in IBM, and older adult patients with gait instability or a history of falls are at high risk for significant falls and fractures. Falls usually occur due to quadriceps weakness causing knees to buckle while standing, turning, or stepping. We refer all patients with prior falls to physical therapy for education regarding interventions to minimize risk of falls. (See
         <a class="medical medical_review" href="/z/d/html/3012.html" rel="external">
          "Falls in older persons: Risk factors and patient evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3014.html" rel="external">
          "Falls: Prevention in community-dwelling older persons"
         </a>
         .)
        </p>
        <p>
         Many patients will benefit from assistive devices such as a cane or walker. Patients with foot drop should be evaluated for ankle foot orthoses (AFOs) that can improve gait dynamics and knee stability. We favor anterior, carbon fiber ground (floor) reaction AFOs that help keep the knee locked during extension. Stance control orthoses (SCOs) stabilize the knee during extension but release to allow flexion during the swing phase of gait and thereby prevent falls due to knee buckling. In a study of nine subjects with IBM, while most patients who used an SCO felt that it improved stability and prevented falls, most patients complained about the size and weight of the device, as well as difficulty putting it on and taking it off due to finger weakness [
         <a href="#rid13">
          13
         </a>
         ]. While there are many different orthotic devices available, our experience is that most patients with foot drop have reduced frequency of falls with AFOs, whereas the difficulty using SCOs limits their utility. (See
         <a class="medical medical_review" href="/z/d/html/16852.html" rel="external">
          "Geriatric rehabilitation interventions", section on 'Orthoses'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H729807997">
         <span class="h3">
          Hand strengthening
         </span>
         <span class="headingEndMark">
          —
         </span>
         The vast majority of IBM patients have significant finger flexor weakness at diagnosis [
         <a href="#rid14">
          14,15
         </a>
         ]. Occupational therapists, especially certified hand therapists, have expertise in improving hand function with splints, adaptive equipment, and exercises. Many types of grip-strengthening devices exist that may help maintain finger flexor function. A single case of a patient having a tendon transfer surgery to improve grip strength in IBM has been reported [
         <a href="#rid16">
          16
         </a>
         ]. At our center, we have seen several patients benefit from this procedure in which an extensor tendon is transferred to a flexor tendon in the forearm (typically extensor carpi radialis brevis tendon to index finger flexor digitorum profundus tendon), enabling wrist extension to power distal finger flexion. This procedure is often done along with a distal interphalangeal fusion to help improve prehension of the index finger. This procedure can be considered in patients with limitation in activities of daily living due to pincher weakness (such as using utensils, buttoning, or writing) who do not have significant wrist extension weakness. A relative contraindication is an inability to stand without use of the limb undergoing the procedure, since the operated arm cannot be used for about six weeks after surgery.
        </p>
        <p class="headingAnchor" id="H3085399157">
         <span class="h3">
          Speech therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately half of patients develop swallowing difficulty during the course of disease, usually due to a combination of oropharyngeal weakness and upper esophageal sphincter (UES) dysfunction [
         <a href="#rid17">
          17
         </a>
         ]. Although there is insufficient evidence to support interventions for dysphagia caused by any chronic, progressive muscle disease [
         <a href="#rid18">
          18
         </a>
         ], we typically refer all patients with any swallowing difficulties to speech therapy for evaluation, and most patients will undergo a video fluoroscopic swallow study with speech therapist guidance. Oropharyngeal weakness may be compensated for by head positioning maneuvers and changes in diet consistency. For UES constriction (typically evidenced by a "cricopharyngeal bar" on swallow study), we recommend balloon dilation by a gastroenterologist [
         <a href="#rid19">
          19
         </a>
         ]. For severe or refractory UES constriction, a cricopharyngeal myotomy can be performed by an experienced otolaryngologist [
         <a href="#rid20">
          20,21
         </a>
         ]. A percutaneous endoscopic gastrostomy (PEG) tube may be required to maintain caloric intake in refractory patients. (See
         <a class="medical medical_review" href="/z/d/html/2237.html" rel="external">
          "Oropharyngeal dysphagia: Clinical features, diagnosis, and management", section on 'Neuromuscular disorders'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H327331684">
         <span class="h3">
          Nutritional support
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with significant dysphagia or in overweight patients, we frequently refer to a nutritionist since malnutrition can exacerbate muscle atrophy and central obesity can contribute to gait imbalance and falls. (See
         <a class="medical medical_review" href="/z/d/html/1617.html" rel="external">
          "Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">
          "Obesity in adults: Overview of management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1985354269">
         <span class="h2">
          Creatine
         </span>
         <span class="headingEndMark">
          —
         </span>
         A placebo-controlled trial has not been performed in IBM, but, given negligible side effects and evidence for improved muscle strength in muscular dystrophy [
         <a href="#rid22">
          22
         </a>
         ], we suggest supplementation with 3 g of creatine monohydrate per day. Some IBM patients find that creatine monohydrate supplementation improves muscle fatigue. (See
         <a class="medical medical_review" href="/z/d/html/5161.html" rel="external">
          "Muscle enzymes in the evaluation of neuromuscular diseases", section on 'Creatine kinase'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3994418356">
         <span class="h1">
          IMMUNOSUPPRESSIVE THERAPY IN SELECTED PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most experts do not recommend immunosuppressive therapy for inclusion body myositis (IBM) [
         <a href="#rid23">
          23,24
         </a>
         ]. However, in some patients with another systemic autoimmune disease (eg, Sjögren's disease) or an atypical presentation, such as rapidly progressive proximal limb weakness, markedly elevated creatine kinase (CK; &gt;15x normal), and/or evidence for severe inflammation out of proportion to fibrosis on muscle biopsy and/or magnetic resonance imaging (MRI), we may initiate a trial of immunosuppressive medication.
        </p>
        <p>
         We discuss potential side effects of glucocorticoid therapy with patients and involve patients in the decision as to whether the small chance of benefit would potentially outweigh the risks. We typically try
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         at a dose of 1 mg/kg per day for about two to three months. In our experience, some patients will show transient but definite improvement in proximal limb weakness or dysphagia despite continued progression of distal weakness.
        </p>
        <p>
         If there is continued decline in strength and function after approximately two to three months of treatment with glucocorticoids, we recommend discontinuation. If there is stabilization or improvement of proximal limb strength, we add
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         (starting at 10 mg/week) or
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         (1.5 to 2.5 mg/kg per day) for a trial period of three to six months and slowly taper the
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose. There are no data to support the use of one of these agents rather than the other. The choice may be determined, in part, by other factors such as concern about hepatotoxicity with methotrexate in a patient with underlying liver disease. (See
         <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">
          "Use of methotrexate in the treatment of rheumatoid arthritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7994.html" rel="external">
          "Pharmacology and side effects of azathioprine when used in rheumatic diseases"
         </a>
         .)
        </p>
        <p>
         All medications should be slowly weaned if there is a continued decline in strength to avoid exposing patients who are non-responders to the toxicity of long-term glucocorticoid and immunosuppressive therapy.
        </p>
        <p class="headingAnchor" id="H2650077094">
         <span class="h2">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoids have not shown efficacy in most studies of IBM patients [
         <a href="#rid2">
          2,25-28
         </a>
         ]. In the largest observational study of 136 IBM patients, 71 patients received immunosuppressants, with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         being the most frequently prescribed drug in over 90 percent [
         <a href="#rid28">
          28
         </a>
         ]. There were no differences in grip strength, CK levels, or deaths between untreated and treated patients, but patients who had been treated were more severely affected on disability scales. In another study of 40 patients with IBM, muscle strength continued to deteriorate in all 25 prednisone-treated patients who were followed for at least two years [
         <a href="#rid25">
          25
         </a>
         ]. Some other reports have noted a partial response to glucocorticoids with either mild improvement in or stabilization of muscle strength [
         <a href="#rid2">
          2,26
         </a>
         ]. Serum CK levels often fall and may even normalize with glucocorticoid therapy; however, this biochemical response does not predict clinical benefit [
         <a href="#rid2">
          2
         </a>
         ]. A 12-year observational study showed that patients treated with steroids long-term had a faster rate of progression to disability than untreated patients, possibly due to steroid-induced myopathy [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H187873211">
         <span class="h2">
          Methotrexate or azathioprine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          Methotrexate
         </a>
         and
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         , alone or in combination, have similarly shown, at best, minor benefit with no complete responses or major improvement [
         <a href="#rid2">
          2,8,26,29
         </a>
         ]. As with glucocorticoids, plasma CK levels often fall and may even normalize with immunosuppressive treatment; however, this biochemical response does not predict clinical benefit [
         <a href="#rid2">
          2,29
         </a>
         ]. This observation was confirmed in a randomized study of 44 patients who received either weekly methotrexate or placebo for 48 weeks [
         <a href="#rid29">
          29
         </a>
         ]. Although the plasma CK decreased significantly in the methotrexate group, there was no significant difference in muscle strength between the two groups (decrease of 0.2 and 3.4 percent for methotrexate and placebo, respectively; 95% CI for the difference in strength between groups -2.5 to +9.1).
        </p>
        <p class="headingAnchor" id="H4271402800">
         <span class="h1">
          AGENTS WITHOUT CLEAR BENEFIT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many drugs that have an immunomodulatory effect have been studied in inclusion body myositis (IBM). Based on limited data, other agents without clear benefit that we typically do not recommend include
         <a class="drug drug_general" data-topicid="10181" href="/z/d/drug information/10181.html" rel="external">
          oxandrolone
         </a>
         [
         <a href="#rid30">
          30
         </a>
         ], intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) [
         <a href="#rid31">
          31-36
         </a>
         ], anti-T-lymphocyte globulin [
         <a href="#rid37">
          37
         </a>
         ], inhibitors of tumor necrosis factor (TNF) alpha (such as
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         ) [
         <a href="#rid38">
          38
         </a>
         ],
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         [
         <a href="#rid39">
          39
         </a>
         ], interferon beta [
         <a href="#rid40">
          40,41
         </a>
         ], or interleukin 1 (IL-1) blockade with
         <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">
          anakinra
         </a>
         [
         <a href="#rid42">
          42
         </a>
         ]. Also, as described above, in most patients there is no clear benefit associated with glucocorticoids [
         <a href="#rid2">
          2,3,25-28
         </a>
         ],
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         [
         <a href="#rid29">
          29
         </a>
         ],
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="local">
          'Glucocorticoids'
         </a>
         above and
         <a class="local">
          'Methotrexate or azathioprine'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravenous
         </strong>
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         – Though some studies have suggested a modest improvement in dysphagia with IVIG, given lack of objective evidence for efficacy, expense, and potential for harm, most experts do not recommend IVIG [
         <a href="#rid43">
          43
         </a>
         ]. In one report, four patients with severe dysphagia due to upper esophageal dysfunction recovered swallowing function after treatment with six to eight monthly infusions of IVIG [
         <a href="#rid44">
          44
         </a>
         ]. In another study of 16 patients treated with a mean of 10 IVIG infusions, IVIG appeared to improve swallowing function in three patients, but the effect was not sustained over the mean follow-up period of 23 months [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most studies on the efficacy of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         in the treatment of IBM do not show evidence for long-term benefit [
         <a href="#rid31">
          31-36
         </a>
         ]. The following studies are illustrative:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A double-blind study randomly assigned 36 patients to either
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         (monthly infusions for three months) or placebo infusions; all patients also received high-dose glucocorticoids [
         <a href="#rid32">
          32
         </a>
         ]. When compared with baseline, there were no significant differences in muscle strength during four months of observation. Follow-up biopsies revealed a greater reduction in the number of necrotic muscle fibers in those who received IVIG than in the placebo group, but this appeared to be of no clinical significance. The authors concluded that the combination of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and IVIG was ineffective in treating IBM.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A double-blind, placebo-controlled crossover study involved 19 patients; no statistically significant improvement in overall muscle strength due to
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         was observed. However, there was a trend toward improvement during IVIG treatment, and nine of the patients continued IVIG therapy independently after the study was concluded because of a sense of improved quality of life [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A double-blind, placebo-controlled crossover study of 11 patients did not suggest any benefit from
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         in muscle strength, symptoms, or myographic test results [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Statins
         </strong>
         – Because of potential antiinflammatory effects of statins, one small pilot study of 10 patients evaluated the safety and efficacy of
         <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">
          simvastatin
         </a>
         40 mg in treatment of IBM [
         <a href="#rid45">
          45
         </a>
         ]. Though no significant benefit was seen, simvastatin appeared to be safe and well tolerated in this small study. In our experience, statins are generally safe in IBM, though given their potential myotoxicity, we recommend minimizing the statin dose and using medications with the lowest potential of myotoxicity such as
         <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">
          pravastatin
         </a>
         and
         <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">
          rosuvastatin
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bimagrumab
         </strong>
         – Bimagrumab is a monoclonal antibody that inhibits the myostatin pathway by binding and inhibiting activin type II receptors (ActRII), which mediate the differentiation and growth of skeletal muscle. By blocking myostatin signaling, bimagrumab can induce muscle hypertrophy [
         <a href="#rid46">
          46,47
         </a>
         ]. Although initial studies with bimagrumab were promising, this benefit was not observed in subsequent long-term studies. A proof-of-concept trial including 14 patients with IBM found that bimagrumab-treated patients had increased muscle mass on magnetic resonance imaging (MRI) at eight weeks when compared with patients who received placebo [
         <a href="#rid46">
          46
         </a>
         ]. No serious adverse events were reported in this small study, and the most common side effects were mild acne and transient, involuntary muscle contractions. A randomized, placebo-controlled phase II trial of 251 patients with IBM found that while bimagrumab failed to meet the primary endpoint of improvement in the 6-minute walk test (6MWT) at 12 months, there was a statistically significant improvement in lean body mass and self-reported physical function [
         <a href="#rid48">
          48
         </a>
         ]. In an extension of the aforementioned study, continued treatment with bimagrumab was well-tolerated but did not appear to provide a clinical meaningful functional benefit compared with placebo, and the study was terminated early [
         <a href="#rid49">
          49
         </a>
         ]. In another small study that followed 10 patients with IBM who continued bimagrumab for up to 2 years, an increase in muscle mass was also detected, but there was no evidence of clinical improvement [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          AAV1 follistatin
         </strong>
         – Follistatin is a natural hormone that antagonizes the myostatin signaling pathway by binding ActRII and inhibiting its activation [
         <a href="#rid51">
          51
         </a>
         ]. Gene therapy using adeno-associated virus (AAV) is a promising therapeutic strategy for muscle disease, and AAV1-Follistatin can be delivered to muscles via intramuscular (IM) injection, thereby minimizing systemic side effects. IM injection of AAV1-Follistatin led to significant muscle hypertrophy in mice and non-human primates [
         <a href="#rid52">
          52
         </a>
         ]. A small study of AAV1-Follistatin injected into bilateral quadriceps muscles of six IBM patients reported an improvement in six-minute walk time [
         <a href="#rid53">
          53
         </a>
         ], though this interpretation has been questioned based on trial design and post-hoc analysis [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Arimoclomol
         </strong>
         – Arimoclomol is an orally bioavailable small molecule chaperone inducer that inhibits protein aggregation in stressed cells. Arimoclomol has been shown to be effective in animal models of IBM and amyotrophic lateral sclerosis (ALS), and it is both safe and well tolerated in ALS and IBM patients in phase I studies [
         <a href="#rid55">
          55,56
         </a>
         ]. A randomized phase II/III trial of 150 patients failed to meet its primary and secondary endpoints at 20 months, and the open-label extension study was terminated early [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10181" href="/z/d/drug information/10181.html" rel="external">
          Oxandrolone
         </a>
         – Oxandrolone is no longer available in most parts of the world. Additionally, because of the uncertain benefit and concerns for adverse effects, we do not typically recommend its use. A randomized, double-blind, placebo-controlled 12-week crossover study of oxandrolone (10 mg twice a day) in 13 patients showed a small but significant improvement in upper extremity strength and borderline improvement in whole body strength [
         <a href="#rid30">
          30
         </a>
         ]. In this study, the drug was well tolerated; however, there was a significant increase in low-density lipoprotein (LDL), a decrease in high-density lipoprotein (HDL), and an increase in transaminases in most patients. Furthermore, anabolic steroids increase the risk of breast and prostate cancer, and they may have virilizing side effects in females (eg, temporal balding or facial hair). Treated patients should have monitoring of transaminases, cholesterol, and prostate-specific antigen (PSA; in males).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alternative agents
         </strong>
         – Since there are no specific medical treatments to offer, patients frequently inquire about diet, dietary supplements, growth factors, acupuncture, massage, hyperbaric oxygen, electrical stimulation, stem cell injections, and other therapies that have not been studied in IBM. While some of these treatments may have theoretical benefit and minimal risk (eg, antioxidants such as coenzyme Q10), many of these nonconventional treatments are quite expensive and lack evidence for safety or efficacy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H383643">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with inclusion body myositis (IBM) usually progress to disability over a period of years. The older the age at onset of the disease, the more rapid the loss of strength and function [
         <a href="#rid58">
          58,59
         </a>
         ]. As an example, an observational study including 78 patients with biopsy-proven IBM found that patients presenting before age 60 progress to the use of a walker after an average of 10.2 years, and those presenting after age 60 require a walker after only 5.7 years of disease [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         By 15 years, most patients require assistance with basic daily activities, and some will become dependent on a wheelchair or will be confined to bed [
         <a href="#rid28">
          28,60
         </a>
         ]. Natural history studies have not shown reduced lifespan in IBM [
         <a href="#rid60">
          60
         </a>
         ], though most experts agree that IBM can be an indirect cause of death, especially due to aspiration pneumonia in patients with dysphagia [
         <a href="#rid60">
          60,61
         </a>
         ]. Clinically significant diaphragmatic weakness is uncommon, though rare cases of respiratory failure due to respiratory muscle weakness have been described [
         <a href="#rid62">
          62
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5163.html" rel="external">
          "Clinical manifestations and diagnosis of inclusion body myositis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H907967618">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/131149.html" rel="external">
          "Society guideline links: Inclusion body myositis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/578.html" rel="external">
          "Patient education: Polymyositis, dermatomyositis, and other forms of idiopathic inflammatory myopathy (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H382887">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Goals of therapy
         </strong>
         – The primary goal of therapy in inclusion body myositis (IBM) is to optimize muscle strength and function. Given the slowly progressive and variable course of the disease, it can be quite challenging to determine if treatment leads to an objective improvement in or stabilization of muscle strength. (See
         <a class="local">
          'Goals of therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonpharmacologic therapy
         </strong>
         – The optimal treatment for IBM is not known, and most interventions have demonstrated only limited benefit. Nonpharmacologic interventions such as physical therapy, occupational therapy, and/or speech therapy can be helpful in all patients to achieve the following (see
         <a class="local">
          'Nonpharmacologic therapy'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Provide an exercise program to maintain strength as long as possible
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Address concerns about falling and the use of orthoses and assistive devices such as canes and walkers
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Address difficulties with the activities of daily living such as finger flexor weakness
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Help learn techniques to minimize the risk of aspiration in patients with dysphagia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Provide nutritional support or dietary counseling in patients with dysphagia or obesity, respectively
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Creatinine supplementation
         </strong>
         – Given negligible side effects and evidence for improved muscle strength in muscular dystrophy [
         <a href="#rid22">
          22
         </a>
         ], we suggest supplementation with 3 g of creatine monohydrate per day (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Some IBM patients find that creatine monohydrate supplementation improves muscle fatigue. It is also reasonable not to give creatine monohydrate supplementation. (See
         <a class="local">
          'Creatine'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Limited role for immunosuppression
         </strong>
         – In contrast to other inflammatory myopathies such as dermatomyositis and polymyositis, IBM is relatively resistant to standard immunomodulatory therapies. We only consider a trial of immunosuppressive medications in IBM patients with an atypical presentation or in patients with another systemic autoimmune disease (such as Sjögren's disease). (See
         <a class="local">
          'Immunosuppressive therapy in selected patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Many drugs that have an immunomodulatory effect have been studied in IBM. Based on limited data, agents without clear benefit that we typically do not recommend include
         <a class="drug drug_general" data-topicid="10181" href="/z/d/drug information/10181.html" rel="external">
          oxandrolone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         , intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG), anti-T-lymphocyte globulin, inhibitors of tumor necrosis factor (TNF) alpha (such as
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         ),
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         , interferon beta, or interleukin 1 (IL-1) blockade. (See
         <a class="local">
          'Agents without clear benefit'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Patients with IBM usually progress to disability over a period of years. The older the age at onset of the disease, the more rapid the loss of strength and function. By 15 years, most patients require assistance with basic daily activities, and some will need to use a wheelchair or need to stay in bed. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Griggs RC. The current status of treatment for inclusion-body myositis. Neurology 2006; 66:S30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leff RL, Miller FW, Hicks J, et al. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine (Baltimore) 1993; 72:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barohn RJ, Amato AA, Sahenk Z, et al. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 1995; 45:1302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Needham M, Mastaglia FL. Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment. Clin Neurophysiol 2016; 127:1764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saltychev M, Mikkelsson M, Laimi K. Medication of inclusion body myositis: a systematic review. Acta Neurol Scand 2015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yood RA, Smith TW. Inclusion body myositis and systemic lupus erythematosus. J Rheumatol 1985; 12:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen MR, Sulaiman AR, Garancis JC, Wortmann RL. Clinical heterogeneity and treatment response in inclusion body myositis. Arthritis Rheum 1989; 32:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beyenburg S, Zierz S, Jerusalem F. Inclusion body myositis: clinical and histopathological features of 36 patients. Clin Investig 1993; 71:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson LG, Collier KE, Edwards DJ, et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis 2009; 10:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexanderson H. Exercise in inflammatory myopathies, including inclusion body myositis. Curr Rheumatol Rep 2012; 14:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spector SA, Lemmer JT, Koffman BM, et al. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve 1997; 20:1242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnardottir S, Alexanderson H, Lundberg IE, Borg K. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med 2003; 35:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernhardt K, Oh T, Kaufman K. Stance control orthosis trial in patients with inclusion body myositis. Prosthet Orthot Int 2011; 35:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eriksson M, Lindberg C. Hand function in 45 patients with sporadic inclusion body myositis. Occup Ther Int 2012; 19:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lloyd TE, Mammen AL, Amato AA, et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology 2014; 83:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waclawik AJ, Rao VK. Effective treatment of severe finger flexion weakness in inclusion body myositis using tendon transfers. J Clin Neuromuscul Dis 2002; 4:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cox FM, Verschuuren JJ, Verbist BM, et al. Detecting dysphagia in inclusion body myositis. J Neurol 2009; 256:2009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones K, Pitceathly RD, Rose MR, et al. Interventions for dysphagia in long-term, progressive muscle disease. Cochrane Database Syst Rev 2016; 2:CD004303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murata KY, Kouda K, Tajima F, Kondo T. Balloon dilation in sporadic inclusion body myositis patients with Dysphagia. Clin Med Insights Case Rep 2013; 6:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darrow DH, Hoffman HT, Barnes GJ, Wiley CA. Management of dysphagia in inclusion body myositis. Arch Otolaryngol Head Neck Surg 1992; 118:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh TH, Brumfield KA, Hoskin TL, et al. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc 2007; 82:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kley RA, Vorgerd M, Tarnopolsky MA. Creatine for treating muscle disorders. Cochrane Database Syst Rev 2007; :CD004760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chhibber S, Amato AA. Clinical Evaluation and Management of Inflammatory Myopathies. Semin Neurol 2015; 35:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalakas MC. Inflammatory muscle diseases. N Engl J Med 2015; 372:1734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain 1989; 112 ( Pt 3):727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol 1992; 19:1385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993; 94:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011; 134:3176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Badrising UA, Maat-Schieman ML, Ferrari MD, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002; 51:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rutkove SB, Parker RA, Nardin RA, et al. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002; 58:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dobloug C, Walle-Hansen R, Gran JT, Molberg Ø. Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients. Clin Exp Rheumatol 2012; 30:838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001; 56:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walter MC, Lochmüller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000; 247:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993; 43:876.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amato AA, Barohn RJ, Jackson CE, et al. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994; 44:1516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003; 61:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barohn RJ, Herbelin L, Kissel JT, et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 2006; 66:S123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009; 132:1536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology 2004; 63:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muscle Study Group. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurology 2001; 57:1566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kosmidis ML, Alexopoulos H, Tzioufas AG, Dalakas MC. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. J Neurol Sci 2013; 334:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012; 78:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002; 58:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sancricca C, Mora M, Ricci E, et al. Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. Neurol Sci 2011; 32:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amato AA, Sivakumar K, Goyal N, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology 2014; 83:2239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lahouti AH, Amato AA, Christopher-Stine L. Inclusion body myositis: update. Curr Opin Rheumatol 2014; 26:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanna MG, Badrising UA, Benveniste O, et al. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol 2019; 18:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amato AA, Hanna MG, Machado PM, et al. Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT. Neurology 2021; 96:e1595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sivakumar K, Cochrane TI, Sloth B, et al. Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis. Neurology 2020; 95:e1971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodino-Klapac LR, Haidet AM, Kota J, et al. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve 2009; 39:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kota J, Handy CR, Haidet AM, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med 2009; 1:6ra15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendell JR, Sahenk Z, Al-Zaidy S, et al. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Mol Ther 2017; 25:870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg SA. Unfounded Claims of Improved Functional Outcomes Attributed to Follistatin Gene Therapy in Inclusion Body Myositis. Mol Ther 2017; 25:2235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cudkowicz ME, Shefner JM, Simpson E, et al. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve 2008; 38:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed M, Machado PM, Miller A, et al. Targeting protein homeostasis in sporadic inclusion body myositis. Sci Transl Med 2016; 8:331ra41.
          </a>
         </li>
         <li class="breakAll">
          https://www.globenewswire.com/news-release/2021/03/29/2200413/0/en/Orphazyme-announces-topline-results-from-pivotal-trial-of-arimoclomol-for-Inclusion-Body-Myositis-IBM.html (Accessed on May 22, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peng A, Koffman BM, Malley JD, Dalakas MC. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology 2000; 55:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortese A, Machado P, Morrow J, et al. Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials. Neuromuscul Disord 2013; 23:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cox FM, Titulaer MJ, Sont JK, et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 2011; 134:3167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price MA, Barghout V, Benveniste O, et al. Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA. J Neuromuscul Dis 2016; 3:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voermans NC, Vaneker M, Hengstman GJ, et al. Primary respiratory failure in inclusion body myositis. Neurology 2004; 63:2191.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5164 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16432142" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The current status of treatment for inclusion-body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8393509" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7617187" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Inclusion body myositis: explanation for poor response to immunosuppressive therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26778717" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26123535" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Medication of inclusion body myositis: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2995660" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Inclusion body myositis and systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2544185" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Clinical heterogeneity and treatment response in inclusion body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8389626" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Inclusion body myositis: clinical and histopathological features of 36 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19494728" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22467380" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Exercise in inflammatory myopathies, including inclusion body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9324080" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Safety and efficacy of strength training in patients with sporadic inclusion body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12610846" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21515888" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Stance control orthosis trial in patients with inclusion body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22495756" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hand function in 45 patients with sporadic inclusion body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24975859" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Evaluation and construction of diagnostic criteria for inclusion body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19078685" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Effective treatment of severe finger flexion weakness in inclusion body myositis using tendon transfers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19603245" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Detecting dysphagia in inclusion body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26859621" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Interventions for dysphagia in long-term, progressive muscle disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23362370" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Balloon dilation in sporadic inclusion body myositis patients with Dysphagia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1313247" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Management of dysphagia in inclusion body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17418072" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17253521" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Creatine for treating muscle disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26502759" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Clinical Evaluation and Management of Inflammatory Myopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25923553" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Inflammatory muscle diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2543478" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Inclusion body myositis. Observations in 40 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1331441" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Inclusion body myositis: analysis of 32 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8386437" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21994327" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Long-term observational study of sporadic inclusion body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11891832" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11940697" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : A pilot randomized trial of oxandrolone in inclusion body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22935197" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11171896" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9065553" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10701893" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8492940" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8058161" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Inclusion body myositis: treatment with intravenous immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12874415" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16432140" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Pilot trial of etanercept in the treatment of inclusion-body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19454532" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15326251" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11706093" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23998706" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22454268" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11805271" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Intravenous immunoglobulin for dysphagia of inclusion body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21695654" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25381300" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Treatment of sporadic inclusion body myositis with bimagrumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25215417" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Inclusion body myositis: update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31397289" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33597289" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32690797" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19208403" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20368179" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Follistatin gene delivery enhances muscle growth and strength in nonhuman primates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28279643" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28927986" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Unfounded Claims of Improved Functional Outcomes Attributed to Follistatin Gene Therapy in Inclusion Body Myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18551622" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27009270" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Targeting protein homeostasis in sporadic inclusion body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27009270" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Targeting protein homeostasis in sporadic inclusion body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10908910" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Disease progression in sporadic inclusion body myositis: observations in 78 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23489664" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21908393" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27854208" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15596785" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Primary respiratory failure in inclusion body myositis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
